Long-term real-world data from Germany's Psoriasis Registry PsoBest indicates that apremilast is a safe and effective treatment for patients with moderate-to-severe psoriatic disease, including those with significant comorbidities. The study, which compiled registry data from January 2015 to June 2020, evaluated 595 patients exposed to apremilast, with 417 receiving it as monotherapy. These findings offer valuable insights into treatment outcomes outside the controlled environment of clinical trials. Patients treated with apremilast were often older and had a higher prevalence of comorbidities like cardiovascular and metabolic diseases, reflecting typical real-world prescribing patterns where apremilast is considered for complex patient profiles. The safety analysis revealed that the most frequently reported non-serious adverse events were drug ineffectiveness (14.1%), diarrhea (9.4%), nausea (7.1%), and headache (6.1%). Incidence rates for infections and infestations were 8.03 per 100 patient-years, and for malignant or unspecified tumors, it was 2.50 per 100 patient-years. Overall, apremilast's safety profile in routine care aligned with previous clinical trial reports. Effectiveness outcomes, assessed at 3, 6, and 12 months post-treatment initiation, demonstrated sustained improvements. The European Medical Journal (EMJ) is described as an online, peer-reviewed, open-access general medical journal with an editorial board of leading authorities and peer review by experts, indicating a credible source of medical information. Apremilast was approved in India by the Drug Controller General of India in October 2017.